Chiang Mai Ram Medical Business Public Co. Ltd.

As of June 30, 2026, Chiang Mai Ram Medical Business Public Co. Ltd. carries a market capitalization of 5.17B, placing it among publicly traded companies globally. Its enterprise value stands at 7.37B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Chiang Mai Ram Medical Business Public Co. Ltd. has 4.07B shares outstanding.

As of June 30, 2026, Chiang Mai Ram Medical Business Public Co. Ltd. trades at a trailing price-to-earnings ratio of 2.14. The price-to-sales ratio is 4.43, and the price-to-book ratio stands at 1.14.

As of June 30, 2026, Chiang Mai Ram Medical Business Public Co. Ltd. trades at an EV/EBITDA multiple of 2.56 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 6.32 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 2.93 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Chiang Mai Ram Medical Business Public Co. Ltd. trades at an EV/FCF ratio of 127.32, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 7.37B versus a market cap of 5.17B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Chiang Mai Ram Medical Business Public Co. Ltd. maintains a current ratio of 0.29, meaning it holds 0.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 47.09, indicating elevated leverage, while an interest coverage ratio of 41.10 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Chiang Mai Ram Medical Business Public Co. Ltd. posted a return on equity (ROE) of 60.65, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 31.70 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 26.50, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 32.86, useful for judging operating efficiency across full business cycles. The company generates approximately 2.36M in revenue per employee across its workforce of 494.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 10.78 indicates how many times Chiang Mai Ram Medical Business Public Co. Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Chiang Mai Ram Medical Business Public Co. Ltd. recorded 47.79M in income tax expense. That works out to an effective tax rate of 1.93, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 2.48B, leaving 2.41B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Chiang Mai Ram Medical Business Public Co. Ltd.'s stock has declined approximately 17.88% over the past 52 weeks. The 50-day moving average sits at 1.26, while the 200-day moving average is 1.32.

Over the twelve months ended June 30, 2026, Chiang Mai Ram Medical Business Public Co. Ltd. generated 1.17B in revenue and converted that into 2.41B in net income, yielding earnings per share of 0.60. EBITDA reached 2.88B, while operating income came in at 103.79M.

As of June 30, 2026, Chiang Mai Ram Medical Business Public Co. Ltd. holds 27.16M in cash and equivalents against 2.17B in total debt, resulting in a net debt position of 2.14B. Total book value stands at 4.54B, with working capital of -1.54B providing operational flexibility.

Chiang Mai Ram Medical Business Public Co. Ltd. produced 404.28M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -415.08M in capital expenditures, free cash flow totaled -10.80M - equivalent to 0.00 per share.

Over the twelve months ended June 30, 2026, Chiang Mai Ram Medical Business Public Co. Ltd. posted a gross margin of 11.76, reflecting its pricing power and cost economics. The operating margin of 8.90 and net profit margin of 206.81 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Chiang Mai Ram Medical Business Public Co. Ltd. paid dividends of 0.34 per share. The dividend payout ratio of 58.65 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -0.21: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 34.40, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Chiang Mai Ram Medical Business Public Co. Ltd. shareholders.

Chiang Mai Ram Medical Business Public Co. Ltd.'s most recent stock split took place on June 8, 2016 with a 1:100 split ratio.

As of June 30, 2026, Chiang Mai Ram Medical Business Public Co. Ltd. has an Altman Z-Score of 1.68, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.